IndiaMedToday Aug 2021

AUGUST 2021, VOLUME 5 ISSUE 8 `200 INDIA MED TODAY

The Last Pandemic Can reform of pandemic prevention and response systems prevent the next pandemic?

AUGUST 2021

PULSE

IMPACT

Keeping Covid at Bay With Proper Sanitation of Hospital Beds

Effective Diagnostics Strategies for Corona Pandemic Mitigation

IMAGING

FEATURE

A Tribute to Nobel Laureate Richard Ernst

Hospital Construction Cost

EDIT NOTE www.indiamedtoday.com

Pandemic Prevention

August 2021 EDITORIAL Editor Neelam Kachhap Sub-Editor Abishek Raj editorial@ indiamedtoday.com

BOARD OF ADVISORS Dr Alexander Thomas

This is the last week of July, and in India, there is hope all around

Dr Girdhar Gyani

that some semblance of normality will return soon. As we wait for

Dr Prem Kumar Nair Dr Bhabatosh Biswas

life to start again, it is still not clear when our hospitals will be free

Dr Alok Roy

from the shackles of COVID-19.

Ramesh Kannan

No doubt that vaccination programmes have brought some relief ART & PRODUCTION ScreeTract Shylesh

CONSULTING EDITOR

from the rising case and have lowered hospitalisation rates. However,

Dr Libert Anil Gomes

vaccination numbers are not encouraging. While, data shows that 30

Dr Salil Choudhary

per cent of the world’s population have now received at least one COVID-19 vaccine, yet in low-income countries only 1 per cent of

ADVERTISING Gunjan Chauhan

people have received at least one dose.

gunjanc@indiamedtoday.com The Media Ant help@themediaant.com DIGITAL MARKETING Vivek Nair Sales & Strategic Partnership Sujit Kaushik sujit.kaushik@indiamedtoday.com EDITORIAL ENQUIRIES editorial@indiamedtoday.com CUSTOMER SERVICE: Subscription support and other assistance for readers subscribe@indiamedtoday.com

Equitable access to vaccines remains a major concern for world leaders as they grapple with the lack of vital medicines and equipment. Many countries are struggling with new virus variant and rising cases and dealing with logistic nightmares. Although, we hear much of global collaboration on vaccine availability and distribution, if some reports are to be believed, it would be more than two years before people in economically challenged countries will be able to receive a vaccine.

Our newest issue focusses on pandemic preparedness and measures that can help us avoid another pandemic. The Cover Story this issue brings to fore the findings of the recent Independent Panel for Pandemic Preparedness and Response and the lessons we can gather from this pandemic to prevent another. It is an honest review of our efforts to contain the present pandemic and clearly outlines our responsibilities and pitfalls.

The report states: ‘[O]ur careful scrutiny of the evidence has revealed failures and gaps in

ADVERTISING ENQUIRIES

international and national responses that must be corrected. Current institutions, public

sales@indiamedtoday.com

and private, failed to protect people from a devastating pandemic. Without change, they will not prevent a future one…We must work together to end this pandemic, and we must

OFFICE 301, Grazia, 1st main, 2nd Cross, Lingrajpuram, Bangalore 560084 www.indiamedtoday.com IndiaMedToday expressly disclaims liability for errors and omissions in this publication. While we try to keep the information timely and accurate, we make no guarantees. The views and opinions expressed in the magazine do not necessarily reflect the official policy or position of IndiaMedToday or the publication. Information on IndiaMedToday should not be used as a substitute for professional healthcare advice. Readers are advised to always seek specialist

act urgently to avert the next. Let history show that the leaders of today had the courage to act.’

Most of our stories and features this issue focus on the implementation of robust prevention and control measures that continues to be a focal point as pressures mount on already stretched healthcare systems around the world, even more so as the pandemic presents new long-term challenges.

Do write-to us and let us know your views. Send in your letters to editorial@indiamedtoday.com

advice before acting on information contained in this publication.

Never disregard professional medicaladvice or delay in seeking it because of something you have read on IndiaMedToday. No part of this publication or any part of the contents thereof may be reproduced, stored in a retrieval system or transmitted in any form without the permission of the publishers in writing.

Printed and published by M Neelam Kachhap, 301, Grazia, 1st main, 2nd Cross, Lingrajpuram, Bangalore 560084 on behalf of Neelam Publishing (OPC) Private Limited, Printed at Paradise Graphics, B-15, Mittal Tower, MG Road, Bangalore-1. and published at 301, Grazia, 1st

Editor M Neelam Kachhap

main, 2nd Cross, Lingrajpuram, Bangalore 560084.

www.indiamedtoday.com

3

AUGUST 2021

CONNECT WITH US Join the conversation with IndiaMedToday through our social media pages Twitter

CONTENTS

21

Facebook

Linkedin

32

30

PULSE

FEATURE

IMAGING

Keeping covid at bay with proper sanitation of hospital beds

Hospital Construction Cost

A tribute to Nobel Laureate Richard Ernst

34 IMPACT

Effective diagnostics strategies for corona pandemic mitigation

24 COVER STORY

The Last Pandemic

UPFRONT

03 Editorial 06 Letters 07 News Roundup 38 Approach www.indiamedtoday.com

CHECKIT OUT ONLINE

TM

Safety Needle with Sharps Injury Prevention SIP SHIELD

Safety from Accidental Needle Injuries

taking care of those who take care of us Hindustan Syringes & Medical Devices Ltd.

Website: www.hmdhealthcare.com, E-mail: info@hmdhealthcare.com

www.indiamedtoday.com

5

LETTERS Physical activity: An essential human need beyond and independent of COVID-19

W

e desperately need to explore both the short- and long-term consequences physical inactivity has on adolescents, and identify effective ways of promoting increases in physical activity, especially in light of the COVID-19 pandemic.

Virtual schooling and social distancing have drastically reduced physical activity and increased the use of screens,

and the consequences of these changes could last a lifetime. Adolescents make up nearly one quarter of the world’s population, and by ensuring that they grow up in social and physical environments that are supportive of physical activity, we are helping to change their health right now, improve their future health, and positively influence the health of the next generation.

Dr Esther van Sluijs, University of Cambridge, UK

For every two COVID-19 deaths worldwide, one child is left

and invest in evidence-based programs and services to protect

Persistent underfunding of the public health system especially primary health care and inadequate health infrastructure in India remain to be addressed by the government even after the devastating second wave. Otherwise, health emergencies will only aggravate existing inequalities and work as a detriment for the poor and the marginalised. Declaring health as a constitutional right can help to bridge these gaps.

and support them right now and to continue to support them

Amitabh Behar, CEO, Oxfam India

behind to face the death of a parent or caregiver. By April 30, 2021, these 1.5 million children had become the tragic overlooked the consequence of the 3 million COVID-19 deaths worldwide, and this number will only increase as the pandemic progresses.

Our findings highlight the urgent need to prioritize these children

for many years into the future – because orphanhood does not

mission consistently.

Most of the times lung cancer is mistaken for tuberculosis in the earlier stages as the symptoms of both diseases are very similar.

In both cases, a patient experiences coughing and or coughing up blood. Smoking continues to be a major cause oflung cancer, the risk of developing lung cancer in smokers versus non-smokers is 20:1.

A passive smoker has an increased chances of contracting cancer than a smoker. For treating the patient at the early stage, surgery is the most important method followed by radiotherapy. Now, more advanced therapy like targeted therapy and immunotherapy options are available which increases overall survival and a leads to better quality of life. Targeted and immunotherapies have fewer side effects compared to chemotherapy. Genetic testing has been a boon in deciding the therapy options leading to better survival rates.

Dr Alexander Kuruvilla, Chief Healthcare Strategy Officer, Practo

Dr. (Brig) S. Viswanath, Medical Oncologist, Kumaran Hospital

go away.

Dr Susan Hillis, U.S. Centers for Disease Control and Prevention COVID-19 Response Team Online consultations have been on a steady rise since the start of the COVID-19 pandemic and the demand persists even after the second wave has passed. As the possibility of a third wave looms over, it becomes even more important to make quality healthcare accessible to people when they need it. Practo stands committed to its mission of helping patients access quality care, 24*7. And it is with the continued support of doctors and other healthcare partners that we have been able to deliver on that

FOLLOW US ON... @indiamedtoday facebook.com/indiamedtoday PLS ADDRESS YOUR LETTERS TO: The Editor, IndiaMedToday and mail to editorial@indiamedtoday.com Pls indicate clearly if you want to publish you views/opinions for this page.

6

August 2021

NEWS ROUNDUP

Sworning in of Mansukh Mandaviya, Health Minister of India

Mansukh Mandaviya sworn in as Union Health Minister

Takeda, Frazier Healthcare partner to launch HilleVax

CII, SII to expand vaccination across small towns, rural areas

Mansukh Mandaviya is the new health minister of India, replacing Dr Harsh Vardhan. Mandaviya’s portfolio assumes utmost significance as the country is amid the coronavirus pandemic. Mandaviya is among the seven ministers of states who have been promoted and given a cabinet rank in today’s cabinet rejig by Prime Minister Narendra Modi. He is a Rajya Sabha MP from Gujarat. Mandaviya will also be in charge of the Ministry of Chemical and Fertilizers. He earlier served as minister of state for ports, shipping and waterways and minister of state for chemical and fertilisers.

Takeda has granted a license to HilleVax

Mandaviya is born in a middle-class farmer family in a village called Hanol, Palitana taluka of Saurashtra’s region Bhavnagar district. He became the youngest MLA at the age of 28 years in 2002. He studied veterinary science at the Gujarat Agricultural University’s Dantiwada and later completed his masters in political science.

outside of Japan. Takeda will retain

The Confederation of Indian Industry (CII) has partnered with Serum Institute of India (SII) to accelerate vaccination in partnership with industry, including healthcare providers. The vaccine drive will target communities in India’s small towns and rural areas to ensure wide coverage. As part of the pan-India vaccine demand aggregation exercise, CII surveyed with a response from over 3000 companies in 196 cities. This identified a requirement of over seven million single-dose vaccines.

CII is now mapping the vaccination need requirement state-wise and setting up vaccination camps along with its members focusing on reaching Tier II / III cities and rural areas.

for

the

exclusive

development

and

commercialisation rights to its norovirus vaccine candidate Takeda Pharmaceutical Company

(Takeda)

and

Frazier

Healthcare Partners (Frazier) announced a collaboration to launch HilleVax, a biopharmaceutical company to develop and

commercialise

Takeda’s

norovirus

vaccine candidate. Takeda has granted a license to HilleVax for the exclusive development

and

commercialisation

rights to its norovirus vaccine candidate, HIL-214 (formerly TAK-214), worldwide commercialisation rights in Japan and

to vaccines and this collaboration allows

Lupin’s subsidiary Generic Health in tie up with Southern Cross Pharma

Takeda to focus primarily on dengue,

Generic Health, an Australia-based wholly-

COVID-19, pandemic influenza and Zika.

owned subsidiary of global pharma major

HilleVax

will

integrate

certain

Japan

development activities into its global development. Takeda remains committed

www.indiamedtoday.com

7

NEWS ROUNDUP Lupin announced that it has entered into a definitive agreement under which Lupin will acquire 100 per cent of the shares of Southern Cross Pharma (SCP).

Incorporated in Melbourne, Australia, SCP is engaged in developing, registering, and distributing generic products. As a part of the transaction, Generic Health will gain access to over 60 registered products having sales of over AUD 30 million (approximately $22 million). This will significantly increase Lupin’s value proposition and market share in the Australian market.

HMD launches 3-Way Stop Cock – Dispoway Hindustan Syringes and Medical Devices (HMD) has introduced 3-way Stop Cock – Dispoway for infusing more than one fluid at a single time. This new and advanced Stop Cock is made with medicalgrade polycarbonate, polypropylene and polyethylene. Dispoway by HMD comes with some modifications that make it an easy-to-use leak-proof product and give healthcare workers better control while infusing fluids. The Stop cock has one male Luer lock with a rotator and two female ports. As a result, the flow of liquids is smooth and the fit is secure. The low dead space design prevents any kind of leakage from occurring.

Evrysdi, oral therapy drug

Roche launches Evrysdi, oral therapy drug to treat SMA Roche announced the launch of Evrysdi (risdiplam), the first and only approved treatment in India for Spinal Muscular Atrophy (SMA) patients. Evrysdi was first approved by the US FDA in August 2020 and is available in India within 11 months of US approval. Since its launch, over 4,000 SMA patients across 50+ countries have benefitted from Evrysdi.

Evrysdi is administered daily at home orally (it is supplied as a powder which is constituted into a liquid solution and taken once daily by mouth or feeding tube if required) and is designed to treat SMA by increasing production of the Survival Motor Neuron (SMN) protein. It is approved for the treatment of spinal muscular atrophy (SMA) in adults and children 2 months of age and older.

GE Healthcare’s India Edison Accelerator unveils Cohort 3 Recognising the emergent need for nextgeneration technologies and diagnostic solutions

in

oncology,

cardiology,

genomics and remote patient monitoring, GE Healthcare’s India Edison Accelerator has announced its Cohort 3 comprising six start-up companies from these areas.

3-Way Stop Cock – Dispoway

8

August 2021

Based out of India and Singapore, these

companies- 4basecare, Haystack Analytics, zMed Healthcare Technologies, Tricog, AIRA Matrix and Qritive – will spend six months with healthcare industry experts from within and outside GE who will help them build and scale up their solutions for new market segments. Applications from startups for Cohort 3 were shortlisted using evaluation criteria such as the strength of the business idea, maturity of product and team capabilities, among others. The India Edison Accelerator provides startups with mentorship, skill development programmes, commercial and regulatory guidance as well as data provisioning.

MoH&FW backs reservation in UG, PG medical/dental courses The Ministry of Health and Family Welfare (MoH&FW) has taken a historic and landmark decision for providing 27 per cent reservation for OBCs and 10 per cent reservation for Economically Weaker Section (EWS) in the All India Quota (AIQ) Scheme for undergraduate and postgraduate medical/ dental courses (MBBS / MD / MS / Diploma / BDS / MDS) from the current academic year 2021-22 onwards. AIQ consists of 15 per cent of total available UG seats and 50 per cent of total available PG seats in government medical colleges. Initially, there was no reservation in AIQ Scheme up to 2007.

In 2007, the Supreme Court introduced a reservation of 15 per cent for SCs and

www.indiamedtoday.com

7.5 per cent for STs in the AIQ Scheme.

When the Central Educational Institutions (Reservation in Admission) Act became effective in 2007 providing for uniform 27 per cent reservation to OBCs, the same was implemented in all the Central Educational Institutions viz. Safdarjung Hospital, Lady Harding Medical College, Aligarh Muslim University and Banaras Hindu University etc. However, this was not extended to the AIQ seats of State medical and dental colleges.

Sathyalok Charitable Trust Dialysis Centre opens in Chennai Sathyalok Charitable Trust Dialysis Centre – Porur, established jointly by Rotary Club of Chennai Capital, Madras West Round Table 10 and Sathyalok Charitable Trust was inaugurated in Chennai. The Tamilnad Kidney Research Foundation (TANKER Foundation) is roped in to provide dialysis services and operate the centre. Among the major donors include Sanjay Lulla, an industrialist. The centre is set to offer it at a subsidised rate of Rs 375 per session. It is also exploring ways to offer the service free of cost in future.

Constructed at the cost of Rs 3 crore, the 20-bed dialysis centre, houses a 5,000 sq ft building, well-equipped with 20 modern

dialysis equipment. It will function from 8 am to 4 pm every day, including Sundays.

The centre is expected to cater to 40 patients a day, impacting in a year close to 15,000 lives who suffer from kidneyrelated issues.

Biocon Biologics, Viatris receive US FDA nod for Semglee Biocon Biologics and Viatris announced that the US Food and Drug Administration (FDA) has approved Semglee (insulin glargine-yfgn injection) as the first interchangeable biosimilar product under the 351(k) regulatory pathway. Biocon Biologics, Executive Chairperson, Kiran Mazumdar-Shaw said, “We are proud to be the first to obtain approval of an interchangeable biosimilar product in the US. It is a milestone achievement for both Biocon Biologics and our partner Viatris.

This will allow pharmacy level substitution and thereby provide convenient and affordable access to Semglee, a quality Biosimilar Insulin Glargine.”

an exclusive license to Biocon Biologics to manufacture and commercialise an antibody treatment based on ADG20 for India and select emerging markets. ADG20, a novel monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses, is in global clinical development by Adagio as a single agent for both the treatment and prevention of COVID-19, the disease caused by the SARS-CoV-2 virus, its variants, as well as future variants that may emerge.

Apollo Hospitals Group, Microsoft India launch Enterprise Solution Apollo 24|7, the digital arm of the Apollo Hospitals Group and Microsoft India have joined hands to launch Enterprise Solution that can be utilised by organisations to provide their employees access to a holistic health and wellness solution within the Microsoft work suite. The Enterprise Solution – as integrated by Apollo 24|7 – has been tested in a pilot programme for Microsoft India employees

Partners with Adagio Therapeutics

for three months.

Biocon Biologics announced that the US-

to this enterprise platform and over 50

based Adagio Therapeutics has granted

per cent of them chose to take virtual

As part of the pilot programme, 5000 Microsoft employees were given access

Sathyalok Charitable Trust Dialysis Centre, Chennai

www.indiamedtoday.com

9

NEWS ROUNDUP consultations with an Apollo doctor during April–June. In addition to virtual consultations, over 2,600 medicine orders were also placed using the App, which was delivered at the doorsteps of the consumers in record time. Each of the registered Microsoft employees had access to over 7,000 doctors and specialists across the Apollo network.

Lung transplant pioneer Jnanesh Thacker joins Yashoda Hospitals Hyderabad Yashoda Hospitals Hyderabad recently announced the joining of Dr Jnanesh Thacker, who will now lead the Institute of Heart and Lung Transplantation for the group. As a Program and Surgical Director of the Yashoda Institute of Heart & Lung Transplantations and Mechanical Circulatory Support (MCS), Dr Thacker will be focusing on the Yashoda Lung Transplant Program. He will have additional practice in heart transplantation, pulmonary endarterectomy and artificial heart implantation (Ventricular Assist Devices) for patients with end-stage heart and lung diseases. Dr Thacker is globally renowned for his mastery in lung transplantation, having been the first surgeon in India to have done a successful lung transplant for an Indian patient in 2012. He was also the first in India to do a successful Minimally Invasive Lung Transplantation in 2013. His special interests lie in minimally invasive lung transplantations done on a beating heart.

Crystal Hearing Solutions centre in Mumbai inauguration

Crystal Hearing Solutions launches centre in Mumbai

units and eight are in the intensive care

Hearing aid specialist Crystal Hearing Solutions inaugurated a new exclusive sound centre in Chembur, Mumbai, marking its foray into the Western region.

With this foray into the Mumbai market, the company plans to target a large number of the population across the city. So far, Crystal Hearing Solutions had been present in the south and suburbs of Mumbai. An authorised platinum partner with Sivantos India (erstwhile Siemens Hearing Instruments ) and brand Signia, Crystal Hearing Solutions is a leading company in the hearing aids segment.

its ability to treat and care for those

Mastercard, AIF launch portable hospital in Jalna Mastercard

and

the

American

India

Foundation (AIF) launched the first 100bed mobile hospital in Civil hospital, Samarth Nagar, Jalna district, Maharashtra.

The facility has been installed by AIF as part of philanthropic efforts delivered through the Mastercard Impact Fund. The newly upgraded facility in Civil hospital, Samarth Nagar, Jalna district, Maharashtra includes triage and treatment centres, of Dr Jnanesh Thacker

10

August 2021

which 92 general ward beds are in isolation

unit (ICU). The addition of 100 new beds increases the hospital’s current 350-bed capacity by almost 30 per cent, boosting affected by COVID-19. Due to the portable nature of the facility, after the urgent need for beds subsides, each unit can easily be deconstructed or repurposed as extra space for various community needs.

Axio Biosolutions raises $6 M in Series B2 equity round MedTech company Axio Biosolutions announced a $6 million Series B2 equity raise led by TrueScale Capital, with participation from existing investors Omidyar Network India, University of California–Ratan Tata Fund, and Accel. Axio Biosolutions, India (Axio), a wholly-owned subsidiary of Boston-based Advamedica is a leading developer of hemostatic and advanced wound care products. With this round of funding, Axio has raised over $20 million to date and plans to build out its commercial presence in the US and EU, as well as strengthen its India operations.

The company is well-positioned to grow in developed markets on the back of its intellectual property, regulatory approvals and clinical data.

Thomson, the creative partner for Aster Hospitals, Kathakali, a popular classical dance form was selected as the medium to communicate the message. A trained Kathakali performer choreographed the performance basis the symptoms to watch for in a stroke patient which was finally woven together in the video by the digital team which included supporting copy.

SpiceHealth launches mobile testing laboratory in Guwahati

NephroPlus ‘Dialysis on Call’ vehicle

NephroPlus launches Dialysis on Call service in Hyderabad

Patki Hospital, Lilac Insights, Mumbai in tie up for IVF treatment

NephroPlus has launched ‘Dialysis on Call’ service in Hyderabad. In Dialysis on Call, a specialised vehicle carries the dialysis machine, consumables, RO water tank, and an expert technician to the patient’s home. After ensuring the pre-requisites, the dialysis is conducted and the vehicle returns to its base location. The overall process is much more comfortable for the patient as they do not need to travel and can get dialysis within the comfort of their homes. One major advantage of this service over regular home hemodialysis services (which NephroPlus already offers) is that the machine and other equipment do not need to be stationed in the patient’s home.

Dr Satish Patki, Senior IVF consultant of Patki Hospital based out of Kolhapur and Dr Sam Balu, Head of Genomics Department at Lilac Insights, a genetic diagnostic testing company jointly announced the success of the path-breaking technology in IVF (test tube baby) treatment called NonInvasive Chromosomal Screening (NICS) of the pre-implantation blastocyst embryos.

A technology that is offered at very few IVF centres across the world.

The process can also help nursing homes and hospitals which do not have dialysis centres for admitted patients who require dialysis. Instead of making these patients travel to another hospital in an ambulance, the Dialysis on Call service team can travel to the hospital/nursing home and conduct the dialysis under the observation of the hospital team.

Patients who wish to avail of this service at their doorstep can call the NephroPlus number (1800120001001) or visit the website.

Patki Hospital in collaboration with Genomics Department of Lilac Insights is carrying out NICS analysis of many blastocysts. Microphotograph of each blastocyst is taken and the correlation of the morphology and the chromosomal make-up of the blastocyst is done.

Aster Hospitals launches digital campaign on strokes Aster Hospitals has launched the #FasterWithAster initiative, a digital campaign set against the backdrop of a popular acronym ‘FAST’- which is exercised to recall the symptoms of a stroke and thus help a person seek prompt treatment. Conceptualised by Wunderman

SpiceHealth has launched its first mobile testing laboratory in Guwahati to conduct Real-Time Polymerase Chain Reaction (RT-PCR) and Rapid Antigen tests. The company’s mobile lab will be stationed at the Indira Gandhi Athletic Stadium whereas the sample collection set-up will be at Lokpriya Gopinath Bordoloi International Airport. The company has partnered with National Health Mission, Assam to set up the facility in Guwahati and will conduct testing at the airport and nearby districts. SpiceHealth operates 23 labs and collection centres spread across ten cities in India. The company operates seven vaccination centres in five states.

Sun Pharma in tie-up with Cassiopea for acne drug in US and Canada Sun Pharmaceutical Industries and Cassiopea, a speciality pharmaceutical company developing and preparing to commercialise prescription drugs with novel mechanisms of action (MOA) to address long-standing essential dermatological conditions announced the signing of License and Supply Agreements for Winlevi (clascoterone cream 1 per cent) in the US and Canada. Winlevi has been approved by the United States Food & Drug Administration (FDA) as a novel drug with a unique mechanism of action for the topical treatment of acne in patients 12 years and older.

Under the terms of the above-referred agreements, Sun Pharma will have the exclusive right to commercialise Winlevi in the US and Canada, and Cassiopea will be the exclusive supplier of the product.

Cassiopea will receive an upfront payment

www.indiamedtoday.com

11

NEWS ROUNDUP of $45 million, potential commercial milestones totalling up to $190 million and customary double-digit royalties. The agreements will close upon the expiration of the HSR waiting period.

Sanaag Specialty Hospital opens in Somaliland doTERRA announced the opening of Sanaag Specialty Hospital, located in Erigavo, the heart of Somaliland’s Frankincense resin harvesting region.

The hospital provides quality, accessible healthcare in a region with over 600,000 people. Working with the Ministry of Health, Ministry of Planning, ResponseMed, and various NGOs over the last four years, doTERRA Healing Hands Foundation and local partners, Jibriil Foundation and Asli-Maydi, funded the construction of the hospital to bring primary and secondary healthcare services to the remote region. The Sanaag Specialty Hospital provides services, including accident and emergency care, maternity and neonatal care, operating theatre (C-sections and surgical procedures), pediatric care, inpatient and out-patient care, diagnostic services (laboratory and radiology), and community outreach. Part of the hospital’s community outreach will include training of maternal-child health and health outpost personnel, regular health day clinics offering maternal and child health checks, as well as the ambulatory response for emergencies.

SERB, GE India in collaboration to promote tech research Soon academic institutes, labs and industries across the country can jointly apply for funds to work on innovations in areas of healthcare, energy and aviation.

This will be facilitated by a collaboration between the Science and Engineering Research Board (SERB), a statutory body of the Department of Science & Technology (DST), Government of India and GE’s John F Welch Technology Centre (JFWTC), Bengaluru, which was launched on July 23, 2021, to promote synergy between academic institutes, labs and industries for research and development in technology across energy, healthcare and aviation sectors. Undertaken as part of the Fund for Industrial Research Engagement (SERBFIRE), the programme aims at supporting research and development to solve critical national and global problems across these key industries. The collaboration will help drive impetus to create a transformative research mindset to foster a novel and impactful research ecosystem in the country.

Rossari to acquire Tristar Intermediates Rossari Biotech, a speciality chemicals manufacturer that provides intelligent and sustainable solutions for customers

across industries, announced that its Board of Directors has approved the acquisition of Tristar Intermediates (Tristar Intermediates, company). As per the agreement and subject to customary closing conditions, Rossari will be acquiring 100 per cent of the equity share capital of Tristar Intermediates. 76 per cent of the equity share capital will be acquired upon closure of the transaction, and the balance 24 per cent over the next three years. The total enterprise value of the transaction is Rs 120 crores. Rossari plans to fund the investment through cash on the balance sheet and doesn’t intend to raise any debt for this acquisition.

Dozee raises Rs 44 crores in Series A funding Dozee, which is in Contactless Remote Patient Monitoring (RPM) solutions, has raised Rs 44 crore in Series A funding.

The funding was led by existing investor Prime Venture Partners, with participation from YourNest Venture Capital and 3one4 Capital. The startup will use the fresh capital in R&D to launch new products and enhance its platform capabilities.

It will also use the funds to increase its presence in HDU ward monitoring, home monitoring, and to deliver a cloud-enabled continuum of care. Dozee has set a goal of partnering with over 1,000 hospitals across India to help them upgrade critical care infrastructure through remote patient monitoring. It plans to install its platform in more than 50,000 step-down ICUs and set up 24×7 Central Monitoring Cells in these hospitals, enabling them to quickly augment the critical HDUs and ICUs and save more than 1 million nursing hours per month.

314e Corporation appoints Dr Sivakumaran Raman as Chief Product Officer 314e

Corporation

announced

clinical

informatics expert Dr Sivakumaran ‘Siv’ Raman as the newest member of its leadership team as their Chief Product Officer. Dr Raman last ran an independent Health IT Consultancy named Lumilla.

Sanaag Specialty Hospital Somaliland inauguration

12

August 2021

Before Lumilla he was the Chief Analytics

www.indiamedtoday.com

13

NEWS ROUNDUP reduced investigations, and improved quality of care. The auto-generation of an electronic healthcare record which is available to both doctors as well as the patient improves collaboration and transparency.

Intas in exclusive licensing agreement with Meiji and Dong-A ST

Dr Sivakumaran Raman Officer at ZeOmega and served as the Staff Vice-President of Data Integration and Clinical Informatics at Anthem, and functioned as Vice President of Clinical Informatics at Optum. Dr Raman was also previously a part of the Institute for Health Informatics’ core faculty at the University of Minnesota.

314e has built an extensive analytics and integration offering under the brand Muspell. Dr Siv Raman will lead the development of offerings under the Muspell umbrella.

PyraMed launches telemedicine platform for joint video consultation PyraMed has launched a telemedicine platform for joint video consultation. The application aims to empower all doctors with

specialist/super-specialist

Intas Pharmaceuticals has entered into an exclusive license agreement with Meiji and Dong-A Socio Holdings (a parent company of Dong-A ST) to commercialise DMB-3115, a proposed biosimilar to ustekinumab, a recombinant monoclonal antibody for the treatment of autoimmune and inflammatory diseases such as plaque psoriasis, Crohn’s disease and ulcerative colitis. Under the terms of the agreement, Intas has been granted exclusive license rights to commercialise DMB-3115 worldwide, excluding Japan, Korea and certain countries in Asia. Meiji and Dong-A ST will develop and manufacture DMB3115 and supply the product to Intas and its worldwide affiliates.

Oasis Fertility launches online portal Oasis Fertility has launched www. worldivfday.in, an exclusive one-stop destination to create awareness, increase knowledge, dispel myths and change mindsets. The site will hold awareness

medical

advice. This will help provide quality medical opinion even in the remotest parts of India at an affordable cost. The ease and capability of accessing specialist opinions will enable the local doctors to make quick and timely decisions for their patients. The patient has only to visit his regular primary doctor. As and when the ailment needs an opinion of a specialist, this primary doctor can video-consult with the relevant specialist, upload all relevant information, and seek an opinion from the specialist in the presence of the patient.

With PyraMed, the primary doctor can bridge the vital gap in telemedicine – inform the physical examination of the specialist, resulting in better diagnosis,

14

August 2021

launch of online portal

sessions, have blogs written by experts, a knowledge section and a Q&A page where people can post queries to be answered by experts.

Ministry of Home Affairs to set up Central Armed Forces Institute of Medical Sciences in New Delhi Ministry of Home Affairs will set up a Central Armed Forces Institute of Medical Sciences (CAPFIMS) in Maidan Garhi, New Delhi. The ministry has invited online submission of Expression of Interest (EoI) from Indian consulting firms/ consultants in healthcare management for rendering consultancy services as Project Development Consultant in the PPP model for operation and maintenance of the medical college. The medical college spread across a 51-acre campus will have a 500bed general hospital, a 300-bed superspeciality hospital, a medical college, a nursing college, a school of paramedics, a 700-seater auditorium, 440 residential quarters for staff, RMOs and doctors, and students’ hostel with recreational facilities.

Freudenberg Medical adds support team in India for customer sales and service Freudenberg

Medical,

part

of

the

Freudenberg Group and a global contract

manufacturing partner to the medical device and pharmaceutical industry, has added a support team in India for customer sales and service to the region.

Freudenberg is committed to serving medical device and pharmaceutical customers also present in the Asia Pacific region with local operations in China and Singapore. Freudenberg Medical designs and manufactures the HelixMark and PharmaFocus Premium brands of silicone tubing for vaccine and drug processing, as well as custom tubing for oxygen concentrators, ventilators, catheters, and other medical devices. The company also provides contract design and manufacturing for medical devices, moulded components, and diagnostic test kits for customers worldwide.

IIT Ropar develops oxygen device AMLEX The Indian Institute of Technology, Ropar has developed a first-of-its-kind oxygen rationing device – AMLEX that supplies a required volume of oxygen to the patient during inhalation and trips when the patient exhales CO2. This process saves oxygen which otherwise unnecessarily get wasted. “The device can operate on both portable power supply (battery) as well as line supply (220V-50Hz)”, said Director, IIT, Ropar, Prof Rajeev Ahuja. It has been developed by PhD students of Biomedical Engineering Department of the institution

– Mohit Kumar, Ravinder Kumar and Amanpreet Chander under the guidance of Dr Ashish Sahani, Assistant Professor, Department of Biomedical Engineering.

It has been developed by PhD students of Biomedical Engineering Department of the institution – Mohit Kumar, Ravinder Kumar and Amanpreet Chander under the guidance of Dr Ashish Sahani, Assistant Professor, Department of Biomedical Engineering.

Novo Nordisk Education Foundation launches diabetes education chatbot Mishti Novo Nordisk Education Foundation (NNEF) launched a WhatsApp Chatbot, Mishti as a one-stop solution for diabetes education in India. NNEF’s Mishti aims to provide easy and quick access to important information to effectively manage diabetes.

Some of the key information services offered by Mishti include insulin device demos, customised diet plans for each patient with exercise guidance based on publicly available information, and scientifically backed research papers.

It is customised in seven different languages (English, Hindi, Bengali, Gujarati, Marathi, Punjabi, and Tamil) so that a greater number of people can access the information in their preferred language.

Medikabazaar strengthens leadership team Medikabazaar has appointed four seniors to strengthen its leadership team across the country. RK Narayanan joins Medikabazaar as the Vice PresidentBusiness Partner for its VPO (Value Purchase Organization) business.

Narayanan brings with him 30 years of rich experience in expanding the business and has previously worked with Boston Scientific handling upstream marketing & CTO programmes. He has also been associated with companies like Philips Healthcare, GE Healthcare, and Indchem Electronics. At Medikabazaar, he will be responsible for supporting the creation of product segments in equipment and devices and expand customer offerings across the VPO business.

Another addition in the VPO business, Manu Dixit joins Medikabazaar as the Business Head for the South and West regions. Dixit will be responsible for OEM tie-ups and will address the procurement needs of all medium and small-size hospitals across the region.

The other two Business Heads who have joined Medikabazaar are Rakesh Gurkha and Chaitanya Sapkal. Gurkha who has joined the dental vertical comes with over 22 years of experience in sales and has been associated with companies like Cortex Dental Implant Industries, Acteon, Danaher and the Kavo Group. He will be leading the business along with the current dental sales team across regions. While Sapkal will be responsible for spearheading and expanding the diagnostic business across India. He brings with him over 20 years of experience in handling sales in the West and South regions and has worked with brands like Abbott Healthcare, Johnson & Johnson, Roche Diagnostics, and Trivitron Diagnostics.

Veeda Clinical Research acquires majority stake in Bioneeds

AMLEX oxygen device

Veeda Clinical Research, a full-service clinical research organisation (CRO) in India, has acquired a controlling 50.1 per cent stake in Bioneeds India (Bioneeds), after acquiring a significant minority

www.indiamedtoday.com

15

NEWS ROUNDUP stake earlier in March. Earlier in June this year, Veeda had also received an equity investment of $16 million led by private equity fund, Sabre Partners and distinguished HNIs like Pranabh Mody (of JB Chemicals), Havells family office, Nikhil Vora (founder of Sixth Sense Ventures), Arjun Bhartia (of Jubilant), amongst others.

Growing R&D budgets of global pharmaceutical companies is the opportunity that Veeda and Bioneeds expect to capitalise on. As per the “Clinical Research Organization (CRO) Market Report” dated May 2021 prepared and released by Frost & Sullivan (India), India is becoming an attractive destination for clinical and preclinical research outsourcing supported by quality scientific capability, the emergence of the biosimilars industry, increased demand for complex generics and availability of a large number of patient volunteers.

Masina Hospital launches certification courses in geriatric care

Launch of post-graduate diploma in Robotics Process Automation

MIT FuSE introduces PG Diploma in Robotics Process Automation

Lupin launches onychomycosis topical solution in US market

MIT Centre for Future Skills Excellence

Lupin announced the US launch of Tavaborole Topical Solution, 5 per cent having received approval from the United States Food and Drug Administration (FDA). The product will be manufactured at Lupin’s facility in Pithampur. Tavaborole Topical Solution, 5 per cent, is the generic equivalent of Kerydin Topical Solution, 5 per cent, of Anacor Pharmaceuticals, and is an oxaborole antifungal indicated for the topical treatment of onychomycosis of the toenails due to Trichophyton rubrum or Trichophyton mentagrophytes. Tavaborole Topical Solution (RLD: Kerydin), 5 per cent has an estimated annual sales of $53 million in the US.

(MIT FuSE), MIT Art, Design & Technology University Pune has introduced a new

Masina Hospital has launched certification courses in association with Tata Institute of Social Sciences (TISS) and MahaArogya Kaushalya Vikas Prashikshan Karyakram.

The courses are directed towards a multibenefit approach of enabling employment amongst the masses and at the same time filling the healthcare staff employment gap. A webinar was organised in the presence of Dr Vispi Jokhi, CEO, Masina Hospital, Tanmay Nayak, Project Director, NUSSD (National University Students’ Skill Development Programme), Tata Institute of Social Sciences and Vijaykumar Ayyer – Project Advisor for NGO (HWARF, Mumbai) & Managing Partner, Sparsh Consultants.

post-graduate diploma in Robotics Process

Metropolis opens testing centre in Palakkad

unique internship opportunities for better

Metropolis Healthcare has launched a new centre in Palakkad, Kerala. The 1,000 sq ft laboratory can conduct more than 60,000 sample testing per month. Sudharma Metropolis Laboratory, Palakkad will offer 4,500 different tests ranging from basic pathology tests to high-end molecular diagnostics tests and can evaluate over 1,000 samples per day. Earlier this year Metropolis Healthcare had launched their second laboratory in the state at Kochi.

16

August 2021

Automation from August 2021, academic session. MIT Art, Design and Technology University

Pune

Memorandum

of

recently

signed

Understanding

a

(MoU)

with CiTiS Infotech & InnoWise Global to jointly offer a PG diploma programme in Robotics Process Automation (RPA). It may be noted that the adoption of RPA across

multiple

global

industries

viz.

healthcare, transport and logistics is rising at a breakneck speed. Any graduate with mathematics at Class XII or equivalent is eligible for the eleven-month programme, which is divided into three trimesters with exposure. The admission announcement with details is available on its official website. MIT-FuSE is also unique in its approach, as it incorporates the greatest industry techniques and technologies into all parts of learning pedagogy, resulting in a genuinely exceptional online learning experience.

All

programmes

will

be

delivered through the LMS and can be accessed via a web-based learning app. In July 2021, the next cohort of SAP, AI/ML, Cloud Computing, and Cybersecurity will begin.

Schneider Electric partners with Kewaunee International for new-age labs Schneider Electric announced a strategic alliance with Kewaunee Scientific Corporation’s International Division. The alliance will embolden Schneider Electric’s advancements in digital transformation and the integration of new-age technologies in the life sciences, healthcare, diagnostic and other segments requiring top-performing laboratories. Schneider Electric and Kewaunee International will commence their operations to traverse across the complete lifecycle of laboratories from

design, build, operation, and maintenance to allow the effective management of smart labs throughout their entire lifecycle. The collaboration will further streamline data analytics, monitoring and laboratory management to create secure networks and mitigate risks to bolster business function.

IIT Madras develops algorithm to identify cancer-causing alterations Researchers from Indian Institute of Technology Madras has developed an artificial intelligence-based mathematical model to identify cancer-causing alterations in cells. The algorithm uses a relatively unexplored technique of leveraging DNA composition to pinpoint genetic alterations responsible for cancer progression.

The research was led by Prof B Ravindran, Head, RBCDSAI, and Mindtree Faculty Fellow IIT Madras and Dr Karthik Raman, Faculty Member, Robert Bosch Centre for Data Science and AI (RBCDSAI), IIT Madras, and also the Coordinator, Centre for Integrative Biology and Systems Medicine (IBSE), IIT Madras. Shayantan Banerjee, a Master’s Student at IIT Madras, performed the experiments and analysed the data.

The results have been recently published in the reputed peer-reviewed International Journal Cancers.

Abbott launches Panbio COVID-19 Antigen Self-Test Abbott has launched Panbio COVID-19 Antigen Self-Test for the detection of the SARS-CoV-2 virus in adults and children with or without symptoms. Self-test kits are offered in packages of one, four, 10 and 20 tests. With results in just 15 minutes, the Panbio COVID-19 Antigen Self-Test enables people who test positive to immediately isolate so that they do not infect others, rather than waiting days for results. Abbott will deliver millions of Panbio COVID-19 Rapid Antigen Tests available for self-use to ease the burden on healthcare systems in urban and rural India. The test is to be used along with Abbott’s NAVICA mobile app, available

Abbott Panbio COVID-19 Antigen Self-Test kit in the Google Play and Apple app store.

The app offers a simple and streamlined process of self-registration, automatic reading of results and easy reporting as per ICMR guidelines. Panbio Self-Tests will be available via retail pharmacies and through e-commerce platforms, as well as through organisations and institutions.

Metropolis Healthcare launches NEXTGEN TB Metropolis Healthcare has launched NEXTGEN TB, whole-genome sequencing of tuberculosis utilising the Next Generation Sequencing (NGS) platform for rapid identification of drug resistance in TB patients and providing genotypic level information on drug-resistant genes for up to 18 Anti – TB antibiotics. Partnering with HaystackAnalytics (start-up incubated at SINE, IIT Bombay), Metropolis Healthcare plans to offer this test in Sri Lanka, Mauritius, the UAE, Kenya, Zambia, Ghana, Tanzania as well as three other African countries to help their fight against tuberculosis.

The 18 drugs covered are Streptomycin, Isoniazid, Rifampicin, Ethambutol, Pyrazinamide, Kanamycin, Amikacin, Capreomycin, Ofloxacin, Moxifloxacin, Gatifloxacin, Ethionamide, Para-amino salicylic acid, Linezolid, Clofazimine, Bedaquiline, Pretomanid, and Delaminid.

IPSC opens centre in Bengaluru Interventional Pain and Spine Centre (IPSC) has launched its first centre in Bengaluru on Bellary Road at Shahkara Nagar. The new

facility,

equipped

with

modular

operating theatres, is staffed with pain specialists skilled in minimally invasive techniques for the management of chronic pain of all types, including joint pain (knee, shoulder, neck, etc.), low back pain, slipped disc, spondylitis/sciatica, neurology pain, migraine, facial pain, rheumatic pain, and cancer-related pain. It also offers capabilities in the prevention and management of sports-related injuries.

The centre’s regenerative department uses natural cells of the body to repair damaged tissues.

DBT-NIBMG creates database of genomic variants of oral cancer DBT-National Institute of Biomedical Genomics (NIBMG), Kalyani an Autonomous Institute funded by the Department of Biotechnology, Government of India has created a database of genomic variations in oral cancer; the first-of-its-kind in the world. NIBMG has made this database publicly accessible. dbGENVOC is a browsable online database of GENomic Variants of oral cancer and is a free resource. The first release of dbGENVOC contains (i) ~24 million somatic and germline variants derived from wholeexome sequences of 100 Indian oral cancer patients and whole-genome sequences of 5 oral cancer patients from India, (ii) somatic variation data from 220 patient samples drawn from the US and analysed

by TCGA-HNSCC project and (iii) manually curated variation data of 118 patients from recently published peer-reviewed publications. Variants were identified by the community approved best practice protocol and annotated using multiple analytic pipelines.

www.indiamedtoday.com

17

NEWS ROUNDUP

Naveen Soni

(L-R) Alan Sachs and Karen E Nelson

Naveen Soni joins Emcure Pharma as Director – Corp Comm

scientific officer (CSO) since 2016, will assume the newly established role of chief medical officer (CMO) and will be succeeded by Karen E Nelson, previously president of the J Craig Venter Institute.

Both will join the company leadership team in August 2021.

Emcure Pharmaceuticals has appointed Naveen Soni as Director – Corporate Communications & Public Relations. His responsibilities include overseeing communications for Emcure Pharmaceuticals. Soni will be working closely with the management at Emcure Pharmaceuticals. Soni comes with over two decades of multi-sector experience in corporate communications, strategic business advocacy, marketing and business journalism. Formerly, Soni has also held communication portfolios in leadership positions with leading Indian MNCs such as UPL, Welspun Group, Wadia Group, Hubtown, and PUG India wherein he was responsible for driving strategic communications and crafting internal and external stakeholder engagement programmes.

Before foraying into the corporate side, he has been an award-winning anchorJournalist with India’s leading business channels including CNBC TV18 and Zee Business. During his media stint, he was responsible for planning, conceptualising and hosting popular shows on stock markets and personal finance.

Thermo Fisher Scientific expands corporate leadership team Thermo Fisher Scientific announced that Alan Sachs, who has served as chief

18

August 2021

Alan Sachs is a physician-scientist who earned his medical and Ph D degrees from Stanford Medical School and has decades of experience supporting product development and clinical research in both therapeutics and diagnostics. In his new role, he will help identify and promote the adoption of new technologies that benefit customers in the clinical space, and he will lead the company’s medical affairs programme.

Karen E Nelson recently joined Thermo Fisher. Nelson who pioneered the human microbiome field received her Ph D from Cornell University. She has authored or coauthored more than 220 peer-reviewed publications, edited three books and is currently editor-in-chief of the journals Microbial Ecology and the newly formed PNAS Nexus. Nelson is an elected member of the National Academy of Sciences and a Fellow of the American Academy of Microbiology.

Healthium buys VitalCare Group in UK

Healthium expand its urology franchise in Europe and other developed markets. With the acquisition of VitalCare, Healthium adds to its manufacturing capabilities in urology and boosts its in-house R&D, which will strengthen its presence in the urology segment in Europe and the US. Lewis Calcutt, MD, VitalCare will continue with the company, building on its global presence and creating a truly differentiated product portfolio.

Healthium has a diverse portfolio of medical devices and consumables, which includes surgical sutures, needles, a patented arthroscopy portfolio, urology portfolio, hernia meshes, haemostats, gloves, ligation clips, surgical staplers and other wound closure devices. The company holds 60 patents in India and the US (including those under process).

Mankind Pharma partners with Ace Turtle Mankind Pharma has partnered with Ace Turtle, a leading omnichannel platform company to accelerate its omnichannel transformation in India. Ace Turtle will enable Mankind Pharma with a Unified Commerce Platform that supports various omnichannel use cases and drive seamless customer experience at scale across digital channels. Powered by machine learning, Ace Turtle’s Unified Commerce Platform,

Healthium, a global player in medical

Rubicon 3.0 supports various omnichannel

devices, has acquired VitalCare Group,

use cases such as inventory lying anywhere

a manufacturer of urology consumable

can be sold across channels, fulfilling

care

orders from any stock points (retail stores,

products,

through

its

subsidiary

Clinisupplies. This acquisition will help

warehouses,

and

distributors)

and

a

single view of the product, inventory, and customer through a single platform.

PLUSS to provide storage solution to Dr Reddy’s for Sputnik V vaccine Pluss Advanced Technologies (PLUSS) will supply its Celsure COVID SURAKSHA box to Dr Reddy’s Laboratories, for optimal temperature-controlled transport and storage for the Sputnik V vaccine, in India.

PLUSS’ patented Celsure box with ‘Phase Change Material (PCM)’ technology will control and maintain the temperature, currently minus 18 degree centigrade (-18°C), required to ensure the efficacy of the Sputnik V vaccine. A separate specialised conditioning centre has been set up locally in Hyderabad with a fleet of Rapid PCM Recharging Stations and mechanisms built for Track and Trace. This model meets the highest standard of coldchain supply management and is highly scalable to meet the country’s demand for vaccine doses in a short period of time.

The Celsure COVID SURAKSHA box can maintain inside temperature passively, without electricity, at desired levels for

more than 100 hours and serve as an energy-efficient and safer alternative to refrigerated containers, conventional ice-packs or even dry ice, which are considered hazardous, unsustainable and unsafe for carrying in airlines.

as working technicians. The partnership

Tech Mahindra Foundation, Wipro GE Healthcare partners

Ramesh Subrahmanian joins Everlife Board

Tech Mahindra Foundation and Wipro GE Healthcare have partnered to offer skilling and upskilling courses to students and healthcare technicians. This partnership will

upskill

existing

paramedics

and

students pursuing radiology technician, operation theatre technician, critical care technician and emergency care technician courses.

The

courses

designed

and

developed by Wipro GE Healthcare will be delivered online, followed by interactive sessions with leading practising industry experts, along with exposure to immersive techniques

and

hands-on

simulators/equipment.

Foundation

(TMF)

will

training

Tech join

on

Mahindra hands

in

offering the training to beginners as well

aims

to

provide

gainful

employment

opportunities for the unemployed youth as well as career progression for working paramedics.

Everlife Holdings, a leading manufacturer and distributor of medical devices and laboratory equipment and consumables in Asia, has appointed Ramesh Subrahmanian to the company’s board of directors.

Subrahmanian currently serves on the board of directors at Healthium, a fastgrowing global medical devices company, while also managing his advisory firm Alchemy Advisors, which helps global clients optimise their growth strategies and organisation models to deliver superior performance.

In his new role as a member of the board at Everlife, Subrahmanian will work closely with the company’s Board, CEO, and leadership team to support the development of the company’s strategic plan including defining the key growth levers, acquisitions, digital footprint, and organisational construct to extend Everlife’s current leadership position in the markets and product segments in which it operates.

Takeda, Frazier Healthcare partner to launch HilleVax Takeda has granted a license to HilleVax for

the

exclusive

development

and

commercialisation rights to its norovirus vaccine candidate Takeda Pharmaceutical Company

(Takeda)

and

Frazier

Healthcare Partners (Frazier) announced a collaboration to launch HilleVax, a biopharmaceutical company to develop and

commercialise

Takeda’s

norovirus

vaccine candidate. Takeda has granted a license to HilleVax for the exclusive development

and

commercialisation

rights to its norovirus vaccine candidate, HIL-214 (formerly TAK-214), worldwide outside of Japan.

PLUSS - Sputnik V vaccine

Takeda will retain commercialisation rights

www.indiamedtoday.com

19

NEWS ROUNDUP in Japan and HilleVax will integrate certain Japan development activities into its global development. Takeda remains committed to vaccines and this collaboration allows Takeda to focus primarily on dengue, COVID-19, pandemic influenza and Zika.

Adroit Biomed launches immunity-enhancing tablets Glutone MD Mumbai-based Adroit Biomed has launched its immunity enhancing tablets Glutone MD, an orally dissolving effervescent tablet formulated with Setria Glutathione from Japan.

Known as The Pocket Warrior, Glutone MD immunity booster tablets have been designed using an Orally Dissolving (ODEff) technology. Glutone MD is an innovative solution and a perfect defence mechanism that acts in two ways and helps prevent

Left to right - Dr. Shampa Brahmachari, Sister Beena, Dr. Susan Sodder, Sister Sneha and Sister Sheela from Holy Spirit hospital COVID-19 infection by strengthening immunity and reducing inflammation and muscle fatigue that aids in recovery from post covid symptoms. Glutone MD is being manufactured in a US FDA Food as well as ANSI National Accreditation Board registered and BSI GMP certified facility and is FSSAI compliant. It is produced at state-of-the-art manufacturing facilities ensuring the highest quality and purity standards. Glutone MD provides potent antioxidant activity, liver protection, immune-boosting, anti-inflammatory and reducing muscle fatigue.

Fujifilm India ties up with Holy Spirit Hospital, Mumbai Fujifilm

India

has

installed

Amulet

Innovality — a breast cancer diagnostic machine at the Holy Spirit Hospital in Mumbai. AMULET Innovality works towards making early detection of breast cancer a reality for women by achieving optimum image quality at a very low patient dose.

It combines Hexagonal Close Pattern (HCP) image capture technology, and intelligent image

processing,

optimising

contrast,

and dose based on breast density which results in exceptional imaging, optimised contrast, low dose, and fast acquisition time.

The Innovality utilises Fujifilm’s

unique a-Se direct conversion flat panel detector (FPD)*1 to produce clear images with a low X-ray dose. This system makes use of intelligent AEC (i-AEC) combined with an image analysis technology to automatically adjust the X-ray dosage for each breast type. It is a highly advanced mammography system, which offers an extremely fast image interval of just 15 Adroit Biomed - Glutone MD tablets

20

August 2021

seconds.

PULSE

Keeping Covid at Bay With Proper Sanitation of Hospital Beds An insight on how proper cleaning process alone annihilates most virus particles on surfaces and keeps in check the spread of infection to a major extent

Team IMT

The organisation and sanitation of healthcare equipment have always been an essential element in the management of any health institute.

A great deal of emphasis needs to be given to this especially after the coronavirus pandemic hit the world last year. With the aggressive spread of the highly contagious virus, cleaning of high touch surfaces and maintenance of reusable pieces of medical apparatus has become exceedingly vital. A proper cleaning process alone annihilates most virus particles on surfaces and keeps in check the spread of infection to a major extent. This is especially indispensable for hospital beds that come in close contact with the patients

for extended periods. Hospital beds are also frequently handled by medical personnel, thus multiplying the chances of contamination. The transmission of pathogens from one patient to another, or medical faculty and others can form a vicious cycle of transfer of infection causing the numbers of those infected to multiply rapidly. If this facet is taken care of, the contagion can be impeded on various levels.

The virus is known to be disseminated through immediate contact with respiratory drops of an infected individual or by physical contact with contaminated surfaces. Albeit confirmed and comprehensive research is yet to

www.indiamedtoday.com

21

PULSE be done, it is assumed that the survival period of viruses on these surfaces is a few hours to several days. The high level of communicability of SARS-CoV-2 makes it even riskier to be left untreated on surfaces. The longer it stays on the surface, the more individuals come in contact with it and are infected. This makes it integral to decontaminate these high-touch surfaces as quickly as possible.

The procedure of cleaning infirmary apparatus authorised by the World Health Organisation includes an initial rinsing with soap or detergent and water, followed by an intricate use of an alcohol-based disinfectant. Application of disinfectants on water sensitive objects should be done after the articles are cleaned with a sterile cloth.

If there is the unavailability of such disinfectants, diluted bleach solutions can be used as an alternative. Bed rails, headboards, other objects on and near beds should be judiciously cleaned following this standard procedure. Other home-based or self-invented products are not advised because such solutions on uninformed usage can result in detrimental consequences.

When using such solutions, it is advisable to read and heed the instructions given by the manufacturer and use specific products suitable for specific surfaces accordingly. Chemicals shouldn't be mixed unless the label on the product explicitly instructs to do so. Wipeable

22

August 2021

or disposable covers are suggested for as many items as possible, particularly electronics and other equipment that cannot be washed to make disinfection an easy and comparatively hassle-free process. Any trivial belonging of the patient left unattended on or around the bed should be carefully discarded with other hospital waste.

Since a lot of research is still in process and plenty of facts have not yet been ascertained, caution and sensibility become imperative when handling medical equipment and other supplies that have come in contact with covid patients. During this cleansing procedure, use disposable gloves, double masks and other protective gear, avoid touching your nose or mouth and practice adequate personal hygiene to prevent yourself from catching the virus. Ample ventilation throughout the cleaning process should be ensured. Since mattresses are exposed to heavy amounts of bodily fluids and secretions, medicines, and other sources of infection, it requires exceedingly meticulous cleaning.

Launder mattresses and other related items in warm water with soap or detergent. Usage of a disposable, nonporous cover over mattresses is highly suggested. Dry all the items completely before reassembling the bed. Once the whole process of disassembling the bed is done, cleaning and sterilising the items and putting black everything

in place, hands need to be washed instantly. Hands should be scrubbed thoroughly for 20 seconds followed by a proper rinse under clean water to get rid of the deadly virus particles completely, and dried with a clean cloth immediately after.

Though there is an introduction of automated cleaning systems lately, they are not suitable for all kinds of surfaces and carry the risk of damaging certain items. Even the heightened efficiency of these automated techniques, manual cleaning and disinfection are relied upon due to the lack of large scale accessibility and availability of these modern technologies. This reliance makes it mandatory to have good knowledge of how to manually clean hospital beds to inhibit the spread of infection. Thus, the health workforce should be well trained to be able to perform this adequately. Workshops and training programmes should be held for the same.

The rampant spread of the virus during the second wave of the pandemic in India caught the poorly developed health infrastructure off-guarded. As the number of patients increased and infirmaries were crowded with patients, there was a shortage of resources,

including beds. New patients were given beds as soon as the previous patients emptied them. Much heed wasn’t given to the sanitation of beds resulting in the virus proliferating rapidly. This instance highlights the importance of on-time sanitation of the hospital equipment and resources, especially beds. The hospital authorities should, thus, be extra cautious with this aspect to prevent the spread of infection. Mattresses should be entirely cleansed each time the patients are switched, whereas other components of the bed including metallic extensions and other items should be cleaned more frequently, preferably daily.

In these trying times, taking responsible steps forward to mitigate the ongoing global crisis becomes incredibly important.

Routine cleaning and disinfection of beds is one such primal step. It should be given heed to by both individuals getting admitted in hospitals and authorities present there. Raising awareness on this subject should be of major concern as it won't only make hospitals more patient-centric, but will also help save multiple lives. These simple measures, when carried out with diligence, can boost the prevention and control of the COVID-19 virus drastically.

www.indiamedtoday.com

23

COVERSTORY

The Last Pandemic

Source: The Independent Panel

Can reform of pandemic prevention and response systems prevent the next pandemic?

24

August 2021

The Independent Panel for Pandemic Preparedness and Response has called on the global community to end the COVID-19 pandemic and adopt a series of bold and essential reforms to prevent the next crisis

www.indiamedtoday.com

25

COVERSTORY Recently, a global panel of leading

Johnson Sirleaf, former President of

experts called to end the COVID-19

Liberia, has spent the past eight months

pandemic by immediately implementing

rigorously

a series of bold recommendations to

on how a disease outbreak became a

redistribute, fund, and increase the

pandemic, and on global and national

availability

responses.

of

and

manufacturing

reviewing

the

evidence

capacity for vaccines, and to apply proven public health measures urgently

The Independent Panel has a total of

and consistently in every country.

13 members, selected by the Co-Chairs.

The Panelists have a substantial mix

“Our message is simple and clear: the

of skills and expertise in infectious

current system failed to protect us

disease, global and national health

from the COVID-19 pandemic. And if

policy

we do not act to change it now, it will

and

not protect us from the next pandemic

advocacy, and the wellbeing of women

threat, which could happen at any time,”

and girls. They also share knowledge

panel Co-Chair and former President

of the international system, including

Ellen Johnson Sirleaf stressed. “The

of WHO, and experience from similar

shelves of storage rooms in the UN and

international processes.

and

financing,

emergencies,

outbreaks

economics,

youth

national capitals are full of reports and reviews of previous health crises. Had

The mission of the Independent Panel is

their warnings been heeded, we would

to provide an evidence-based path for

have avoided the catastrophe we are in

the future, grounded in lessons of the

today. This time must be different,” she

present and the past to ensure countries

added.

and

global

institutions,

including

specifically WHO, effectively address

The Panel

health threats. They have spent the last

The Independent Panel for Pandemic

eight months independently, impartially,

Preparedness

and

(The

and rigorously reviewing evidence of

Independent

Panel)

appointed

the spread, actions, and responses to

by

the

World

Response was

Health

Organization

(WHO) Director-General in response to a World Health Assembly resolution, 73.1 for

issued an

in

May

independent,

2020,

calling

impartial,

and

comprehensive review of experiences gained and lessons to be learned from the current pandemic. They were also asked to provide recommendations to improve capacity for global pandemic prevention, preparedness, and response.

The Panel released its findings and recommendations in its main report: COVID-19: Make it the Last Pandemic which was released in May 2021.

The Panel, co-chaired by the Rt Hon Helen Clark, former Prime Minister of New Zealand, and Her Excellency Ellen

26

August 2021

The Panel found that the system as it stands now is unfit to prevent another novel and highly infectious pathogen, which could emerge at any time, from developing into a pandemic.

“A

key

that

finding

of

accountability

the

Panel

is

for

pandemic

preparedness and response has been lacking across the system. National governments are the primary dutybearer

in

pandemic

response,

and

the lack of accountability has been accompanied by a failure to learn from mistakes and take up the opportunity for learning between countries,” the report said.

Key Recommendations As the COVID-19 pandemic continues to devastate communities across the the COVID-19 pandemic. They have conducted numerous literature reviews, original research and have learned from dozens of experts in roundtable discussions and in-depth interviews.

The Panel has also heard directly from people working on the front-line of the pandemic in town-hall-style meetings and has invited contributions from anyone wishing to make one.

report

demonstrates

a series of immediate recommendations to halt its spread. It recommends that: High-income countries with a vaccine pipeline for adequate coverage should, alongside their scale-up, commit to provide to the 92 low and middleincome countries in the COVAX Gavi Advance

Market

Commitment

with

at least one billion vaccine doses by September 2021.

Failure to Respond The

world, the Independent Panel is making

that

the

Major

vaccine-producing

countries

current system—at both national and

and

international levels— was not adequate

under the joint auspices of the WHO

to

and

protect

people

from

COVID-19.

manufacturers the

World

should

Trade

convene,

Organization

The time it took from the reporting

(WTO) to agree to voluntary licensing

of a cluster of cases of pneumonia of

and technology transfer. If actions on

unknown origin in mid-late December

this don’t occur within three months,

2019 to a Public Health Emergency of

a waiver of intellectual property rights

International Concern being declared

under the Agreement on Trade-Related

was too long. February 2020 was also a

Aspects of Intellectual Property Rights

lost month when many more countries

should come into force immediately.

could have taken steps to contain the spread of SARS-CoV-2 and forestall the

The G7 should immediately commit to

global health, the social, and economic

providing 60 per cent of the $19 billion

catastrophe that continues its grip.

required for the Access to COVID-19

www.indiamedtoday.com

27

COVERSTORY

Tools Accelerator (ACT-A) in 2021 for vaccines,

diagnostics,

stop this happening again,” she added.

therapeutics,

and strengthening of health systems,

The report also shared recommendations

and a burden-sharing formula should

for individual countries, including that

be adopted to fund such global public

heads of state and government should

goods on an ongoing basis.

appoint national pandemic coordinators who are accountable to them, and who

Every country should apply proven

have a mandate to drive whole-of-

public health measures at the scale

government coordination for pandemic

required

to

curb

the

pandemic.

Leadership from heads of state and government to achieve this is crucial.

“Given the scale of devastation from this

pandemic

and

its

continuing

impact on people across the globe, the Panel resolved to document fully what happened and why, and to make bold recommendations for change,” Panel Co-Chair Rt Hon. Helen Clark, said.

preparedness and response.

The Panel also released the report and recommendations together, with a range of background papers which include the authoritative chronology of what happened. This is the culmination of multiple literature reviews, original research, discussions with experts in roundtables and in-depth interviews, and dialogue with those working on

“The tools are available to put an end to

the front-line, with women and youth

the severe illnesses, deaths, and socio-

in town hall-style meetings. It also

economic damage caused by COVID-19.

received online contributions to its

Leaders have no choice but to act and

work.

28

August 2021

The Panel has consistently raised its

dispatch experts to investigate at the

deep concern that the burden of the

shortest possible notice.

current pandemic is being unevenly shared. It has had devastating social

• Invest in national preparedness now

and financial consequences for those

as it will be too late when the next

already

125

crisis hits. All governments should

million more people are estimated

review their preparedness plans and

to have been pushed into extreme

allocate the necessary funds and

disadvantaged.

Up

to

poverty, while 72 million more primary school-age children are now at risk of being unable to read or understand a simple text because of school closures.

Women have borne a disproportionate burden. Gender-based violence is at record levels, and child marriages have increased. In addition, the world lost $7 trillion in GDP in 2020 – more than

people required to be prepared for another health crisis.

• Transform the current ACT-A into a truly global platform aimed at delivering

global

including

vaccines,

public

goods

diagnostics,

therapeutics, and supplies that can

the 2019 GDP of the entire African

be distributed swiftly and equitably

continent ($6.7 trillion). The pandemic

worldwide—shifting from a market

has caused the deepest shock to the

model to one aimed at delivering

global economy since World War II.

global public goods.

Prevention Strategies

• Focus and strengthen the authority

The world must also urgently prepare to prevent a future outbreak from becoming a pandemic. To this end, the Independent Panel calls for the engagement of heads of state and government to lead efforts to transform the existing system. The Panel calls for a series of bold and forward-looking reforms, including:

and financing of the WHO, including by developing a new funding model to end earmarked funds and to increase Member State fees.

• Create an International Pandemic Financing

Facility,

which

would

have the capacity to mobilise long term (10-15 year) contributions of approximately $5-10B per year to

Health

finance ongoing readiness. It would

Threats Council that will maintain a

also be ready to disburse from

political commitment to pandemic

$50-100B at short notice by front-

preparedness

and

loading future commitments in the

hold actors accountable, including

event of a pandemic declaration. The

through

Global Health Threats Council would

• Establishing

a

Global

and

peer

response

recognition

and

scrutiny. Countries should also adopt a Pandemic Framework Convention within the next six months.

• Establish for

a

new

surveillance

global based

allocate and monitor the funding to institutions that can support the development of preparedness and

system on

full

transparency. This system would provide the WHO with the authority

response capacities.

• Heads of state and government should at a global summit adopt

about

a political declaration under the

outbreaks with pandemic potential

auspices of the UN General Assembly

on

to commit to these transformative

to

publish an

information

immediate

basis

without

needing to seek approval and to

reforms.

www.indiamedtoday.com

29

FEATURE

Hospital Construction Cost Cost control in construction with tech is the new normal

Akhil Ganatra, Managing Director, Clancy Global

The pandemic

has

impacted

most

industries globally. As it is, the annual productivity

growth

in

construction

averaged barely 1per cent over the previous two decades, compared to 3.6 per cent for the manufacturing sector and 2.8 per cent for the global economy, respectively and COVID is only going to worsen this.

While many sectors have been able to sustain productivity, thanks to the ability to function remotely, productivity in the construction industry witnesses further challenges, due to resource availability, raw material costs and accuracy of remote visibility.

30

August 2021

What’s more, it is pushing promoters to miss project deadlines, have fluctuating cash flow, tackle statutory requirements, affect time to revenue and related stunted mitigation opportunities.

Considering this scenario there is a need to adopt technologies that enable agile yet sound construction practices more than ever before.

Today, we are the first to have 2D interactive technology to facilitate quick, easy and accurate assessment of on-ground activities. A single source of truth across design quantification, recording day-to-day progress and bill certification.

This significantly optimises effort, input costs and alignment across stakeholders. Impact on cash flow, mandays and variation to design quantity is pinpointed.

the conventional monitoring tools, the digital platforms not only enable multilevel resource control daily but also facilitates work progress measurements on a unified platform.

Pre-construction stage

The platform also offers a convenient visualization option for remote visibility and a progressive audit via 3D scanners.

We see that planning is one of the most critical aspects and a cost control framework is to be set from the schematic stage.

With our cost control platform, design stage quantification is done 6 to 10 times faster than 3D BIM. As mandated, 3D BIM is also achieved 2 to 3 times faster. The 2D interactive form ensures continuity of information for day-to-day progress reporting and bill verifications.

Collapsed timelines translate to, savings in overhead, shorter time-frame, online cash flow and high predictability of resources.

Construction Stage Another crucial aspect of project execution is to continuously monitor the cost and progress to avoid budget and time over-runs. As opposed to

While the construction industry, traditionally has been resistant to tech adoption, the mounting pressure to cut costs and meet stringent market demands will propel technologies to ensure project transparency, enhance customer experience, streamline overheads and deliver value.

Annual productivity growth in construction averaged barely 1per cent over the previous two decades

www.indiamedtoday.com

31

IMAGING

A Tribute to Nobel Laureate Richard Ernst Team IMT

Photo Source: https://chab.ethz.ch/en/

Richard Ernst Swiss physical chemist Richard Ernst who was known for his contribution to the development of high resolution nuclear magnetic resonance (NMR), recently died at the age of 87. Ernst received the 1991 chemistry Nobel prize for his work in NMR. Born in Winterthur, Switzerland on August 14, 1933, Ernst earned his PhD in physical chemistry in 1962 from ETH Zurich and completed his dissertation was on nuclear magnetic resonance in the field of physical chemistry.

He worked as a research chemist for Varian Associates in California, US, one of Silicon Valley’s first high-tech companies. Ernst joined ETH Zurich in 1970 as an assistant chemistry professor. There he met famous scientists, like Weston A Anderson, Ray Freeman, Jim Hyde, Martin Packard, and Harry Weaver.

Still in Varian, one of major importance for the success of more advanced experiments and measurement techniques in NMR was the availability of small laboratory computers that

32

August 2021

could be hooked up directly to the spectrometer. During his last years at Varian (1966-68), Ernst developed numerous computer applications in spectroscopy for automated experiments and improved data processing (Source: www.nobelprize. org).

Back in Switzerland, Ernst had a chance to take over the lead of the NMR research group at the Laboratorium für Physikalische Chemie of ETH-Z. Despite an initial lack of suitable instrumentation, he continued to work on methodological improvements of time-domain NMR with repetitive pulse experiments and Fourier double resonance. In addition, he along with other scientists performed the first pulsed time-domain chemically-induced dynamic nuclear polarisation (CIDNP) experiments.

Ernst also developed stochastic resonance as an alternative to pulse FT spectroscopy employing binary pseudorandom noise sequences for broadband excitation, correlating input and output noise.

In 1968 Ernst returned to Switzerland after an extensive trip through Asia.

A brief visit to Nepal made him turn toward Asian art, especially towards Tibetan scroll paintings, the so-called thangkas, a unique and most exciting form of religious art. He invested a large part of the prize money into his Tibetan art collection.

except in a voluntary and excellent

Ernst retired in 1998 after having been associated at ETH Zurich for nearly three decades and a full professor for more than 20 years. He headed a research group at the university and focussed on magnetic resonance spectroscopy and served at one point as director of the physical chemistry lab. ETH Zurich even named a lecture series after him in 2009.

and also sat on the editorial boards of

According to www.nobelprize.org, Ernst mentioned, “A book from which I learned a lot at that time was Theoretical Chemistry by S Glasstone.

It revealed to me the fundamentals of quantum mechanics, spectroscopy, statistical mechanics, and statistical thermodynamics, subjects that were never even mentioned in lectures,

Ernst delivered lectures on magnetic

lecture course given by the young enthusiastic Professor Hans H Günthard who had studied chemistry and physics in parallel.”

Ernst also served as the President of ETH Zurich’s Research Council, as a member of the Swiss Science Council 10 scientific journals. He also belonged to the US National Academy of Sciences, the UK’s Royal Society, the German National Academy of Natural Sciences Leopoldina, the Russian Academy of Sciences and the Korean Academy of Science and Technology.

Post his retirement from ETH Zurich, resonance spectroscopy, the historical development of spectroscopy and the analysis of pigments in paintings using Raman spectroscopy.

Ernst apart from receiving the Nobel Prize was awarded seven honorary doctorates.

He

also

received

the

Wolf Prize in Chemistry in 1991 for ‘revolutionary contributions to NMR spectroscopy, transform

especially and

Fourier-

two-dimensional

NMR’. Besides this, he received the Horwitz Prize (1991), and the Marcel Benoist

Prize

(1986).

He

received

more than a dozen honorary doctors degrees, among them degrees from ETH Lausanne, Technische Universität Munich, Universität Zurich, University Bern, University Antwerpen, BabesBolyai University Cluj-Napoca, Charles University

Prague,

and

University

Montpellier. He is a member of the US National Academy of Sciences, of the Royal Academy of Sciences, London, of the Deutsche Akademie Leopoldina, of the Russian Academy of Sciences, of the Korean Academy of Science and Technology, and an honorary member of many further societies.

Photo Source: https://new.in-24.com/News/5538.htm)

Richard Ernst

Ernst is survived by his wife and three children, the Swiss news agency ATS.

www.indiamedtoday.com

33

IMPACT

Effective Diagnostics Strategies for Corona Pandemic Mitigation With an array of ICMR-approved tests available in the market, it will be offer better time efficiencies by reducing the turnaround time

The corona pandemic has globally disrupted lives and livelihood. We have already had two strong waves in India, causing widespread agony, suffering, deaths, and mental trauma.

Jatin Mahajan, Managing Director, J Mitra & Company

While lockdown, movement curbs, and social distancing/masks are effective in mitigating the risk of communicability and preventing the spread of the virus, a more effective strategy is required for testing and monitoring to counter the third wave.

India's current testing strategy rests on rapid antibody tests and RT-PCR tests. Unfortunately, both these testing strategies have limitations – the rapid antibody tests are stop-gap tests in nature. An RT-PCR test must follow them in case of a negative result. But in an estimated 90 per cent of the cases, this SOP is not followed. As a result, these people continue to intermingle in markets, offices, and homes, and invariably the false-negative patients end up infecting others as well.

Although the RT-PCR test is the gold standard in COVID-19 testing, it is relatively expensive and out of reach for much of the financially challenged populace. Also, RT-PCR requires highend equipment, which is not available in rural and semi-urban India, making this form of testing unviable for most of the rural population in the country.

There are far more effective techniques

34

August 2021

available in the market and already approved by ICMR. The COVID-19 Ag Microlisa Elisa Antigen Test is one of the best known and viable alternatives. The Elisa Antigen Test is ideal for contact tracing and is as reliable as the RTPCR tests, yet cost significantly less.

They don't need extensive equipment or a high-cost workforce and can be deployed even in rural areas. Their cost-effectiveness makes them a more preferred choice for the masses. The Elisa Antigen Tests are also more timeefficient, and results are available at a fraction of time as needed for the RTPCR test.

The Elisa Antigen test can provide an impetus to India's fight against COVID-19 by significantly bringing down the overall cost of testing. These tests also offer better time efficiencies by reducing the turnaround time between testing and results to just two hours.

India already has thousands of Elisa readers with laboratories across the country to read the test results. Positive patients can be quickly isolated. This test will minimise uncertainty and confusion for the masses due to prolonged test results – to ascertain whether it is safe to interact or isolate and quarantine.

Another critical aspect of the corona pandemic mitigation strategy is the need for monitoring the effectiveness of the vaccination and the development of antibodies within our citizens.

The COVID-19 Neutralizing Antibody Microlisa test is critical to India's fight against the corona pandemic because it showcases how effective the vaccination has been for creating neutralizing antibodies against the SARS-CoV-2 virus.

Virus neutralisation is the gold standard for deciding antibody efficacy, and neutralising antibodies help form an individual's passive immunity. It provides short-term immunity to a healthy individual against disease.

Neutralizing antibody (NAb) is responsible for defending cells from pathogens, which cause disease (in this case, SARS-CoV-2). NAb are produced naturally by the body as part of its immune response, and infections and vaccinations against infections trigger their production.

Testing of antibodies is ideal for serosurveillance and seroprevalence.

Many countries are now testing for SARS-CoV-2 antibodies at the population level or in specific groups, such as health workers, close contacts of known cases, or within households, and taking necessary corrective actions. These antibodies (in High Titer) determine

if the individual has good humoral immunity, donate convalescent plasma, and if the vaccination is successful.

In addition, these antibodies help in segregating patients between mild, moderate, and severe categories. Hence they act as an advanced diagnostic marker against the resurgence of COVID infections.

WHO supports these studies as they are critical for understanding the extent of and risk factors associated with infection. Some of the countries that have implemented SARS-CoV-2 antibodies testing for monitoring the development of herd immunity include – the US, the UK, Australia, China, Thailand, Germany, Sweden, Austria, Switzerland, Finland, Brazil, Iceland, Spain, amongst others. This strategy should be immediately implemented in India as well to counter the threat of the third wave.

The fight against the corona pandemic is a long and tedious one. These two are robust solutions for the diagnostic labs to fast-pace India's comprehensive monitoring and detection process. We must wake up to the challenge and include these aspects mentioned above as an integral part of the country's

www.indiamedtoday.com

35

IMPACT strategy to counter the pandemic. If we do, we will emerge through the crisis with far fewer losses, agony, and financial burden.

Healthcare innovations for post-pandemic world Architects and healthcare professionals need to relook at the design of healthcare facilities The COVID-19 pandemic has changed the definition of the normal for most of us. Hospitals around the world have crumbled under the weight of the virus. The uncertainty has altered the way we live, travel, work and our perceptions about health and safety.

Technology has changed care, efficiency and improvement in healthcare, and it’s time that architects and healthcare professionals relook at the design of these healthcare facilities.

Today, healthcare practitioners and designers worldwide are working in tandem to bring about fundamental changes in healthcare design and its implementation. At CDA, we believe

36

August 2021

that the probable future road map of changes will revamp the medical service sector in the most accurate meaning of the word. As architects, we refute the argument that the inevitable solution to a collapsing healthcare system is to build more infrastructure, like metaphorical crutches holding up a dilapidated entity. Health futurists and researchers are now focused on orienting the healthcare system towards a more digitally seamless care delivery model that attempts to retain the innate essence of care through technology.

Two possible stages anticipate major reorientation of the system’s antiques.

The first one being, the hospital-centric model, which will employ tools like AI and Big Data to comprehend patterns out of the already existing profile of patients and use them for creating dynamic, iterative design layouts for hospitals. This model will look to inform itself from the ever-growing pool of healthcare statistics and data to develop digitally transformable floor plans within the hospital. This system will be aided by app-based scheduling and

consultation for each patient, which will smartly manage the masses that would wait in endless queues. The dependence on care providers such as nurses can be eased with the help of advanced logistic support mechanisms to cut down on unnecessary displacement to provide for medicines, linens, testing samples, etc.

After boosting the efficiency of the healthcare system, the second stage will move a step further and reduce the dependency on the hospital facility itself. The hospital building will dwindle in size, cut down on consultation, diagnostic, and in-patient departments, and retain only intensive care units and critical care. A patient’s health will be monitored by smart infrastructure linked via the cloud to the hospital, which will provide remote healthcare while in the comfort of one’s own home.

There will be a facility for virtual nursing and online interactions with the caregivers for enhanced support. The architecture of such ‘Smart Infrastructure’ would have to be completely cloud-collaborated, optimisable, and friendly to autonomous mobility such as drones, etc., allowing for interior access, movement, unloading, and parking; suggests the paper. This will reduce healthcare costs and be a

giant leap towards ensuring accessible care and medical service to all.

From a healthcare design standpoint, architects need to look beyond functionality. In a post-pandemic world, healthcare designers need to set forth innovative solutions that seamlessly blend altruism with technology to create a robust ecosystem, the benefit of which is bifold. These solutions will render high-quality medical care to those in need and focus on patient safety, satisfaction, and comfort at present. Additionally, it will streamline future care delivery by constantly collecting and analysing patient data through tech-enabled infrastructure. To augment a seamless transition to digital and smart care delivery, healthcare designers should incorporate research in care delivery and equipment technology and analysis in the planning stages to result in flexible infrastructure.

As architects at CDA, we understand the criticality of designing adaptable, sustainable, and responsive hospitals, focusing on patient care and experience.

With a commitment to improving the healthcare scenario in India, we are optimistic that with architects working in partnership with doctors, researchers, policymakers and tech giants, an evolved healthcare ecosystem awaits.

www.indiamedtoday.com

37

APPROACH

Impact of COVID-19 Vaccine Vaccination has had an impact in reducing hospital expenses, mortality and the average length of stay among COVID-19 patients. Excerpts from the Star Health study.

A first-of-its-kind retrospective cohort study on the impact of vaccination among COVID-19 patients was conducted by Star Health and Allied Insurance. The study unveiled the significant impacts of vaccination among individuals 45 years. The aim of this study was to study the impact of vaccination on reducing the average length of stay (ALOS), intensive care unit (ICU) requirement, mortality and cost of the treatment among COVID-19 patients.

The Study In this retrospective cohort study, all the patients above 45 years who underwent treatment for COVID-19 were included.

38

August 2021

The data of patients treated pan India during the period March and April 2021 with the diagnosis of COVID-19, under health insurance cover, were extracted to study parameters like the ALOS, mortality, ICU requirement, total hospital expenses incurred and the vaccination status.

Study parameters like the Average length of stay (ALOS), mortality, intensive care unit (ICU) requirement, total hospital expenses and the vaccination status (first or second dose, time-lapse in contracting disease among the vaccinated; and reasons for not vaccinating among the rest) were procured from the case

records submitted. Wherever further information was required, the patients or their relatives were contacted through a telephone call. The parameters were compared between the unvaccinated and vaccinated groups. Results were expressed as percentage, mean (s.d) and compared using the chi-square test or student’s t-test using graph-pad prism software and the difference was considered significant if the p-value was less than 0.05.

Reasons for not taking COVID vaccine (n=3301)

A total of 3820 patients with COVID-19 were analysed. Among this group, 3301 (86.4 per cent) were unvaccinated while 519 (13.6 per cent) were vaccinated. A total of 486 (12.7 per cent) patients had received the first dose, while 33 (0.8 per cent) had received the second dose. In 43 per cent of the unvaccinated group, there was no valid reason for the same.

Table 1 describes the other reasons among the unvaccinated (apprehension/ fear 21 per cent, ignorance 14per cent; recent infections 9 per cent; social factors 7 per cent and lack of interest 6 per cent).

unvaccinated, the mean (s.d) ALOS was

Fourteen days after second doses of

seven days. Fourteen days after the

vaccination this was

Speaking on the study, Dr S Prakash, MD, Star Health and Allied Insurance said, “The beginning of 2021 saw a breakthrough in vaccine discovery against COVID-19 making it the fastest vaccine discovery till date. Our aim was to measure and understand in exact terms the impact of Covid-19 vaccination in patients who contracted the illness 14 days after the second dose versus unvaccinated patients, thus making it unique research in its own right."

Dr Madhumathi Ramakrishnan, Joint VP Star Health and Allied Insurance said, “Our study covered pan India data of the patients affected by COVID-19.

The aim was to assess the medical and financial implications of vaccination.

Our study concluded that the ones who had taken the vaccination had a clear advantage over the non-vaccinated as we witnessed a significant difference in parameters like a hospital stay, cost of treatment and death due to infection."

Figure 1(a) and hospital

describes expenses.

No valid reason

1420

43%

Apprehension/Fear

693

21%

Ignorance regarding age eligibility

462

14%

Recent other infections

297

9%

Family commitment/Social factors

231

7%

Disinterested

98

6%

second dose of vaccination this was significantly less (p=0.01) at 4.9 days.

The mean total hospital expense among the unvaccinated was Rs. 277850.

further less (p=0.001) at Rs.217850 (figure 1b).

Figure 2 compares ICU requirements

ICU stay based on vaccination status ICU Stay in those who received 1 dose-30/486 (6%)

Vaccinated n=519

ICU Stay in those who received 2 doses-1/33 (3%)

Total COVID Patients n=3820

ICU Stay 291/3301 (8.8%)

Unvaccinated n=3301

between the groups. Among the unvaccinated population, 291/3301 (8.8%) required ICU stay and this was significantly less (p=0.03) at 31/519 (6%) among the vaccinated. Among those who received two doses of vaccination, it was further less at 1/33 (3 per cent).

The relative risk of ICU stay among the unvaccinated population was 0.34 (95 per cent C.I 0.49 – 2.37) and there was a 66 per cent relative risk reduction in

ICU stay after two doses of vaccination.

The

mortality

among

unvaccinated

patients was 16/3301 (0.5 per cent) while there was no mortality among the vaccinated patients (table 2). The relative risk of mortality among the unvaccinated population was 0.19 (95 per cent CI0.02-3.20) and there was 81 per cent relative risk reduction in mortality by vaccination.

the ALOS Among the

www.indiamedtoday.com

39

APPROACH Co-morbidity and outcomes.

Comorbid conditions

DM/HTN or both

Un-vaccinated

Vaccinated

Significance

(n=3301)

(n=3301)

(pvalue)

1177/3301 (36%)

239/519 (46%)

0.001

7.7 (3.06)

5.9 (3.04)

0.001

Treatment cost in rupees mean (s.d)

294421 (30697)

251302 (31176)

0.001

ICU required

111/1177 (9.4%)

12/239 (5%)

0.03

ALOS

Table 3 sub-classifies the outcomes among those with co-morbidities.

Among the vaccinated patients, comorbidities were found in 239/519 (46 per cent) and this was significantly higher (p=0.001) than 1177/3301 (36 per cent) noted in the un-vaccinated group. Despite having higher comorbidities ALOS, ICU requirement and hospital expenses were significantly less (table 3) among the vaccinated.

Limitations There are several limitations to this study. Being a retrospective cohort study, in analysing vaccination status among COVID-19 patients, Star Health and Allied Insurance were unable to comment on the incidence of disease among the vaccinated/unvaccinated population. The study covered patients under health insurance cover who are treated in private settings, thus excluding a larger population treated at government hospitals. However, it covers pan-India data and is likely to represent a national trend. Further, this study focused only on those aged 45+ and happened during the early phase of vaccination when scepticism was high and vaccine penetration was low.

The study mentioned that only hospitalised patients, while a larger proportion of milder cases postvaccination could have been treated as in outpatient or at-home care settings. The study also did not cover

40

August 2021

asymptomatic cases that could have happened post-vaccination. The study did not have details of the strain that could have been responsible for the break-through infection. Also, it was difficult to assess the baseline immune status of the population that could have attributed to this.

Conclusion The study concluded that there was a marked reduction in the total hospitalisation expenses by approximately 24 per cent, the average length of stay (ALOS) by a mean of 2.1 days, ICU requirement by 66 per cent and a reduction of approximately 81 per cent in mortality among patients who had completed two doses of vaccination.

COV

vacc ID-19 ine

The Evolving Cybersecurity Landscape Remote working has increased cyberthreats.

But even after the global pandemic is over, it’s going to be important to take actionable steps to combat the sizable security risks.

Customized MVISION Device-to-Cloud Suites MVISION Advanced

|

MVISION Premium

|

MVISION Complete

We Recommend:

Implement a cloud-based secure web gateway

1 2 3 4 5 6

Require multi-factor authentication to reduce risks of credential theft

Set policy in the cloud for routine device checks

https://www.mcafee.com/enterprise/en-us/assets/reports/restricted/rp-carr-wfh.pdf https://www.mcafee.com/enterprise/en-us/assets/reports/restricted/rp-carr-wfh.pd Source: https://www.darkreading.com/cloud/as-cloud-adoption-grows-dlp-remains-key-challenge/d/d-id/1335000 https://newsroom.ibm.com/2020-07-29-IBM-Report-Compromised-Employee-Accounts-Led-to-Most-Expensive-Data-Breaches-Over-Past-Year https://www.gartner.com/smarterwithgartner/is-the-cloud-secure/ https://media.nominet.uk/wp-content/uploads/2019/02/12130924/Nominet-Cyber_CISO-report_FINAL-130219.pdf

8 https://www.mcafee.com/enterprise/en-us/assets/reports/rp-cloud-adoption-and-risk-report-work-from-home-edition.pdf McAfee and the McAfee logo are trademarks or registered trademarks of McAfee, LLC or its subsidiaries in the US and other countries. Other marks and brands may be claimed as the property of others. Copyright © 2020 McAfee, LLC. 4619_0920 SEPTEMBER 2020

www.indiamedtoday.com

41

42

August 2021